VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors
Open Access
- 6 June 2016
- journal article
- Published by Springer Nature in Oncogene
- Vol. 36 (1) , 1-12
Abstract
The inadequate transport of drugs into the tumor tissue caused by its abnormal vasculature is a major obstacle to the treatment of cancer. Anti-vascular endothelial growth factor (anti-VEGF) drugs can cause phenotypic alteration and maturation of the tumor’s vasculature. However, whether this consistently improves delivery and subsequent response to therapy is still controversial. Clinical results indicate that not all patients benefit from antiangiogenic treatment, necessitating the development of criteria to predict the effect of these agents in individual tumors. We demonstrate that, in anti-VEGF-refractory murine tumors, vascular changes after VEGF ablation result in reduced delivery leading to therapeutic failure. In these tumors, the impaired response after anti-VEGF treatment is directly linked to strong deposition of fibrillar extracellular matrix (ECM) components and high expression of lysyl oxidases. The resulting condensed, highly crosslinked ECM impeded drug permeation, protecting tumor cells from exposure to small-molecule drugs. The reduced vascular density after anti-VEGF treatment further decreased delivery in these tumors, an effect not compensated by the improved vessel quality. Pharmacological inhibition of lysyl oxidases improved drug delivery in various tumor models and reversed the negative effect of VEGF ablation on drug delivery and therapeutic response in anti-VEGF-resistant tumors. In conclusion, the vascular changes after anti-VEGF therapy can have a context-dependent negative impact on overall therapeutic efficacy. A determining factor is the tumor ECM, which strongly influences the effect of anti-VEGF therapy. Our results reveal the prospect to revert a possible negative effect and to potentiate responsiveness to antiangiogenic therapy by concomitantly targeting ECM-modifying enzymes.Keywords
This publication has 56 references indexed in Scilit:
- TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stromaProceedings of the National Academy of Sciences, 2012
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancerGut, 2012
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal AdenocarcinomaCancer Cell, 2012
- Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formationProceedings of the National Academy of Sciences, 2011
- Up-regulation expressions of lysyl oxidase family in Anterior Cruciate Ligament and Medial Collateral Ligament fibroblasts induced by Transforming Growth Factor-Beta 1International Orthopaedics, 2011
- Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumorsProceedings of the National Academy of Sciences of the United States of America, 2011
- Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to TumorsCancer Research, 2010
- Modulation of Lysyl Oxidase-like 2 Enzymatic Activity by an Allosteric Antibody InhibitorJournal of Biological Chemistry, 2010
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and InvasionCancer Cell, 2008
- Percutaneous vertebral compression fracture management with polyethylene mesh-contained morcelized allograft boneCurrent Reviews in Musculoskeletal Medicine, 2007